Obermatt
See Similar Stocks →

Chunghwa Chemical Synthesis & Biotech

TAI:1762 · TW0001762003
PharmaceuticalsX-Small

360

13
Medium confidence — indicative
EV / EBIT1
Price / Owner Earnings100
Owner Earnings Yield1
Dividend Yield1
Price/Sales24
EV / Gross Profit9
Price/Book52
Return on Capital43
Cash Return on Capital54
Return on Equity46
EBIT Margin10
Gross Profitability14
Accruals65
Owner Earnings Margin45
Sales growth98
Profit Growth14
Owner Earnings Growth21
Reinvestment48
Price momentum82
Debt load59
Refinancing47
Debt Payback1
Liquidity12
Analyst ratings1
Expectations trend50
Market mood1
Value Creation0/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Chunghwa Chemical Synthesis & Biotech doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryTaiwan
IndustryPharmaceuticals
SizeX-Small
TypePublic Company
ExchangeTWSE
Employees17
Websiteccsb.com.tw
ISINTW0001762003
Last UpdateApr 2, 2026
Index & Theme
CardiovascularImmunologyOncologyCentral Nervous SystemBiotechnologyHealth CareManufacturingPharmaceutical

Description

Analysis

Hope premium

Chunghwa Chemical Synthesis & Biotech Co., Ltd. is priced well ahead of what the underlying numbers justify, a pattern we describe as a hope premium.

Valuation data is not available for this company.

Growth is moderate; the safety picture is adequate. The company scores 0/20 on our value-creation score: not creating value.

Flags to be aware of: Some accounting patterns deserve a closer look. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
26
2023202420252026

All-time high

100

Jan 2023

All-time low

10

Mar 2026

Average rank

48

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
24
51
57
63
Price/Earnings
100
26
97
95
Price/Book
52
83
65
63
Dividend Yield
1
64
67
65
Value (overall)
19
54
80
73

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Chunghwa Chemical Synthesis & Biotech with its peers
PKC
KSC:001340
12
CountrySouth Korea
IndustryChemicals
SizeSmall
Full Stock Analysis →
NOVONIX
ASX:NVX
8
CountryAustralia
IndustryElectronic Equipment, Instruments & Components
SizeSmall
Full Stock Analysis →
Kukje Pharma
KSC:002720
43
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
PharmGen Science
KSC:004720
74
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Hana Pharm
KSC:293480
88
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Reyon Pharmaceutical
KSC:102460
16
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →